Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMO06JV)

Drug Name

Mitoflaxone Drug Info

Synonyms

Flavone acetic acid; flavone-8-acetic acid; 87626-55-9; LM-975; NSC-347512; Mitoflaxone [INN]; NSC 347512; Mitoflaxonum [INN-Latin]; Mitoflaxona [INN-Spanish]; 4H-1-BENZOPYRAN-8-ACETIC ACID, 4-OXO-2-PHENYL-; UNII-X230G6E63B; 2-Phenyl-8-(carboxymethyl)-benzopyran-4-one; NSC347512; 4-Oxo-2-phenyl-4H-1-benzopyran-8-acetic acid; BRN 4260339; MLS003171055; TZZNWMJZDWYJAZ-UHFFFAOYSA-N; X230G6E63B; Mitoflaxonum; Mitoflaxona; C17H12O4; Flavoneacetic acid; LM 975; Flavone-8- acetic acid; AC1L1JPE; NCIStruc2_000951; Flavone acetic acid; FAA, Merck; Flavone acetic acid, Merck; Flavone-8-acetic acid

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Terminated	[1]

Cross-matching ID

PubChem CID: 55748
CAS Number: CAS 87626-55-9
TTD Drug ID: DMO06JV

Molecule-Related Drug Atlas

Molecule Type:

DTT

DOT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting von Willebrand factor (VWF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vonvendi	DMI783H	Von willebrand disease	3B12	Approved	[4]
Caplacizumab	DMPUKA7	Thrombotic thrombocytopenic purpura	3B64.14	Approved	[5]
Recombinant von Willebrand factor/recombinant Factor VIII complex	DM7JFDO	Von willebrand disease	3B12	Phase 3	[6]
ALX-0081	DM7EBH9	Thrombotic thrombocytopenic purpura	3B64.14	Phase 3	[7]
ARC1779	DM7PCLY	Intracranial embolism	8B22.1	Phase 2	[8]
BT-200	DM1EYOF	Von willebrand disease	3B12	Phase 2	[9]
DA-697b	DMBRN2G	Thrombosis	DB61-GB90	Phase 1	[10]
DTRI-031	DM0BCT7	Ischemic stroke	8B11.5Z	Phase 1	[11]
Auryntricarboxylic acid (ATA)	DMOIQ4K	Discovery agent	N.A.	Investigative	[2]
------------------------------------------------------------------------------------


⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
von Willebrand factor (VWF)	TT3SZBT	VWF_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
E3 ubiquitin-protein ligase XIAP	OT24GP9B	XIAP_HUMAN	Drug Response	[3]

------------------------------------------------------------------------------------

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000745)
2	Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci. 2002 Jan;23(1):25-32.
3	Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res. 2000 May;6(5):1796-803.
4	Clinical pipeline report, company report or official report of Vonvendi.
5	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
6	6 Factor VIII Concentrates, Factor VIII/von Willebrand Factor Concentrates, Factor IX Concentrates, Activated Prothrombin Complex Concentrates. Transfus Med Hemother. 2009 December; 36(6): 409-418.
7	Clinical pipeline report, company report or official report of Ablynx
8	Short-Acting Anti-VWF (von Willebrand Factor) Aptamer Improves the Recovery, Survival, and Hemostatic Functions of Refrigerated Platelets. Arterioscler Thromb Vasc Biol. 2019 Oct;39(10):2028-2037.
9	Clinical pipeline report, company report or official report of Guardian Theapeutics
10	A new oral antiplatelet agent with potent antithrombotic properties: comparison of DZ-697b with clopidogrel a randomised phase I study. Thromb Haemost. 2010 Jan;103(1):205-12.
11	Clinical pipeline report, company report or official report of Basking Biosciences